---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-006626"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:12:55.405550+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Sangamo Therapeutics files prospectus supplement for up to $204M in ATM sales

## Summary
- Remaining ATM capacity of $204.1M under $325M Sales Agreement with Jefferies LLC as of March 7, 2023.
- Filed Amendment No. 3 to the Open Market Sale Agreement to reflect the remaining shares.
- Filed legal opinion from Cooley LLP on validity of the common stock offered.

## SEC filing metadata
- accession: 0001628280-23-006626
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828023006626/0001628280-23-006626-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828023006626/sgmo-20230307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-006626
- JSON: https://secwatch.observer/filing/0001628280-23-006626.json
- Plain text: https://secwatch.observer/filing/0001628280-23-006626.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.